Eversept Partners LP Sells 93,838 Shares of AnaptysBio, Inc. $ANAB

Eversept Partners LP reduced its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 77.6% in the 1st quarter, HoldingsChannel.com reports. The fund owned 27,089 shares of the biotechnology company’s stock after selling 93,838 shares during the period. Eversept Partners LP’s holdings in AnaptysBio were worth $1,502,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its position in AnaptysBio by 78.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 10,166 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 4,484 shares during the period. Affinity Asset Advisors LLC raised its holdings in shares of AnaptysBio by 111.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock valued at $52,132,000 after purchasing an additional 495,308 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of AnaptysBio by 19.1% in the 1st quarter. Renaissance Technologies LLC now owns 90,900 shares of the biotechnology company’s stock worth $5,041,000 after purchasing an additional 14,600 shares during the period. Sei Investments Co. lifted its position in shares of AnaptysBio by 54.1% in the 1st quarter. Sei Investments Co. now owns 7,654 shares of the biotechnology company’s stock worth $424,000 after purchasing an additional 2,688 shares during the period. Finally, Walleye Capital LLC bought a new position in shares of AnaptysBio during the first quarter valued at approximately $1,022,000.

AnaptysBio Stock Down 1.0%

Shares of AnaptysBio stock opened at $53.61 on Tuesday. The firm’s 50 day moving average price is $58.28 and its 200-day moving average price is $57.64. AnaptysBio, Inc. has a 52-week low of $11.40 and a 52-week high of $72.36. The company has a market cap of $1.59 billion, a P/E ratio of -49.64 and a beta of 0.68.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The company had revenue of $25.56 million for the quarter, compared to the consensus estimate of $18.86 million. As a group, equities research analysts forecast that AnaptysBio, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANAB has been the topic of several research reports. UBS Group lifted their price objective on shares of AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Piper Sandler lowered their target price on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Leerink Partners set a $90.00 price target on AnaptysBio in a report on Friday, May 15th. Finally, Barclays boosted their price target on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $82.00.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.